<DOC>
	<DOCNO>NCT00372619</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , clofarabine cytarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose clofarabine give together cytarabine see well work treat young patient refractory relapse acute myeloid leukemia acute lymphoblastic leukemia . ( Phase I close enrollment 09/16/09 )</brief_summary>
	<brief_title>Clofarabine Cytarabine Treating Young Patients With Refractory Relapsed Acute Myeloid Leukemia Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To define overall response rate ( complete remission remission without platelet recovery ) young patient relapse refractory acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) treat clofarabine combination cytarabine . Secondary - To determine safety profile tolerability clofarabine give combination cytarabine patient without prior stem cell transplantation . - To identify apoptosis specific gene important mediate response clofarabine cytarabine . - To quantitate level human equilibrative nucleoside transporter protein ( hENT1 hENT2 ) human concentrative nucleoside transporter protein ( hCNT2 hCNT3 ) blast patient . - To determine gene expression profile study entry time relapse order isolate profile may predict response also complement apoptosis specific protein array . - To perform serial measurement minimal residual disease ( MRD ) provide objective determination effectiveness treatment regimen correlate post remission event ( relapse , death ) . - To perform FLT3/ITD analysis help determine prevalence clinical significance somatic mutation patient relapse AML . OUTLINE : This multicenter , phase I , dose-escalation study clofarabine follow phase II study . Patients stratify accord disease ( acute lymphoblastic leukemia [ ALL ] v acute myeloid leukemia [ AML ] ) . ( Phase I close accrual 09/16/09 ) - Intrathecal CNS prophylaxis ( patient ALL physician 's discretion patient AML acute leukemia ambiguous lineage ) : Patients receive intrathecal ( IT ) cytarabine day 0 first course induction therapy . Patients also receive IT methotrexate day 1 second course induction therapy day 1 course maintenance therapy . - Induction therapy : - Course 1 : Patients receive cytarabine IV 2 hour clofarabine IV 2 hour day 1-5 . Patients ≥ 5 % blast ( i.e. , M2 M3 bone marrow ) day 14-21 proceed immediately course 2 induction therapy . Patients &lt; 5 % blast ( i.e. , M1 bone marrow ) may proceed course 2 induction therapy blood count recovery day 42 . - Course 2 : Patients receive clofarabine IV 2 hour follow cytarabine IV 2 hour day 1-5 . After second course induction therapy , patient M2 M3 bone marrow day 14-21 remove study . Patients M1 bone marrow proceed maintenance therapy 14-42 day initiation course 2 . - Maintenance therapy : Patients receive clofarabine cytarabine induction therapy . Treatment repeat every 14-42 day 10 course absence disease progression unacceptable toxicity . Patients may undergo blood bone marrow sample collection periodically correlative laboratory study . After completion study therapy , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 87 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Acute myeloid leukemia ( AML ) ≥ 5 % blast bone marrow ( M2/M3 bone marrow ) without extramedullary disease Acute lymphoblastic leukemia ( ALL ) &gt; 25 % blast bone marrow ( M3 bone marrow ) without extramedullary disease Acute leukemia ambiguous lineage ≥ 5 % blast bone marrow ( M2/M3 bone marrow ) without extramedullary disease Disease must relapse refractory prior induction therapy Patients AML acute leukemia ambiguous lineage must first relapse OR refractory first induction therapy ≤ 1 attempt remission induction Patients AML enroll phase I portion study must receive prior mitoxantrone hydrochloride cytarabine newly diagnose AML ( phase I close accrual 09/16/09 ) Patients ALL must second third relapse ( ≤ 3 prior induction regimen ) OR refractory reinduction first relapse Patients ALL refractory first induction therapy eligible No acute promyelocytic leukemia No CNS 3 involvement ( i.e. , WBC ≥ 5/μL cerebrospinal fluid blast present cytospin ) PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 50100 % ( &gt; 16 year age ) OR Lansky PS 50100 % ( ≤ 16 year age ) OR ECOG PS 02 Life expectancy ≥ 8 week Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min Direct bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT &lt; 2.5 time ULN ( unless relate leukemic involvement ) Shortening fraction ≥ 27 % echocardiogram OR ejection fraction ≥ 45 % gate radionuclide study No evidence dyspnea rest exercise intolerance Pulse oximetry &gt; 94 % room air Amylase ≤ 1.5 time ULN Lipase &lt; 1.5 time ULN No active , uncontrolled grade 3 4 infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment No known hepatitis B C infection history cirrhosis PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy* At least 14 day since prior cytotoxic therapy ( except hydroxyurea intrathecal chemotherapy ) * At least 7 day since prior biologic agent* At least 14 day since prior monoclonal antibody therapy* No 1 prior autologous allogeneic hematopoietic stem cell transplantation No evidence active graftvshost disease At least 4 month since transplantation No concurrent chemotherapy immunomodulating agent No concurrent investigational therapy NOTE : *Patients relapse ALL maintenance therapy require wait period .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
</DOC>